$NXTS News

Nexentis Subsidiary MitoCareX Hits First Drug‑Discovery Milestone With Optimized Molecule

Nexentis Technologies' Subsidiary Receives U.S. Patent And Trademark Office Official Trademark Registration For Its MITOLINE Algorithm Platform

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nexentis Technologies Announces Launch Of Its New Corporate Website At www.nexentistech.com

N2OFF Rebrands To Nexentis Technologies, Changes Ticker To NXTS, Effective Feb. 26

MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

N2OFF Says MitoCareX Bio Shows Preliminary In Vitro Data Demonstrating Inhibition Of Pro‑Inflammatory Responses In Human Immune Cells Using Its Proprietary Discovery Platform

In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions

N2OFF Highlights Peer‑Reviewed Study In Journal of Translational Medicine By MitoCareX Bio Co‑Founder On SLC25A Mitochondrial Carriers As Biomarkers And Therapeutic Targets For Spaceflight‑Induced Dysfunctions

Wall Street Set to Open Higher Thursday as Investors Parse GDP, Unemployment Data, Look Ahead to Inflation Report

N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform

N2OFF Says MitoCareX Bio Shows Preliminary In Vitro Data Demonstrating Inhibition Of Pro‑Inflammatory Responses In Human Immune Cells Using Its Proprietary Discovery Platform

N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions

N2OFF Highlights Study Authored By MitoCareX Bio Co-Founder Ciro Leonardo Pierri On Mitochondrial Carriers in Spaceflight Stress Conditions

N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake

N2OFF Advances German Solar Projects With Reduction In Permitting And Regulatory Risk Across Core European Assets; Sees ~$1.7M Value Creation, With Multiple High-Visibility Pathways To Value Realization Beginning In H2 2026

N2OFF Accelerates European Renewable Energy Momentum with Major De-Risking Milestones and Approximately $1.69 Million Value Unlock in Germany and Italy

N2OFF Collaborates With Solterra Renewable Energy To Enhance European Portfolio

N2OFF: MitoCareX Identifies Hit Compounds and Targets Preclinical Candidate Nomination